Kezdőlap・Részvénylista・Editas Medicine Inc

Editas Medicine Inc

Lezárt

SzektorEgészségügy

2.87

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.81

Maximum

3.02

Fő mutatók
By Trading Economics
Bevétel	6.8M -18M
Értékesítés	9.1M 12M
Egy részvényre jutó nyereség	-0.15
Profit margin	-153.322
Munkavállalók	87
EBITDA	3.9M -20M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+171.19% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 9.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	25M 432M
Előző nyitás	2.87
Előző zárás	2.87

Hangulat hírek alapján

By Acuity

63%

37%

279 / 340 Rangsor szerint Healthcare

Editas Medicine Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 11. 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

2026. aug. 10. 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

2026. aug. 7. 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026. aug. 6. 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

2026. aug. 5. 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

2026. júl. 31. 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

2026. júl. 30. 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

2026. júl. 29. 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

2026. júl. 28. 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

2026. júl. 27. 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

2026. júl. 24. 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

2026. júl. 22. 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

2026. júl. 21. 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Társak összehasonlítása

Árváltozás

Editas Medicine Inc Előrejelzés

Célár

By TipRanks

171.19% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8 USD 171.19%

Magas 15 USD

Alacsony 4 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Editas Medicine Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Editas Medicine Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

279 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.